|

Angiopoietin and Adverse Outcomes in Cardiac Surgery

RECRUITINGN/ASponsored by Centre Hospitalier Universitaire, Amiens
Actively Recruiting
PhaseN/A
SponsorCentre Hospitalier Universitaire, Amiens
Started2023-03-23
Est. completion2026-04
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05817929

Summary

Cardiac surgery and cardiopulmonary bypass can lead to systemic organ failure trough excess inflammation and endothelial injury. The angiopoietin family represented by angiopoietin 1 and 2 can reflect endothelial injury by a decrease in angiopoietin 1 and an increase in angiopoietin 2. The investigators hypothesized that angiopoietin dysregulation could reflect organ failure related to cardiac surgery. The purpose of this project is to assess the association between angiopoietin dysregulation and adverse outcomes on cardiac surgery.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* adult patient scheduled for cardiac surgery under cardiopulmonary bypass

Exclusion Criteria:

* patient less than 18 years old,
* redo surgery,
* urgent surgery,
* endocarditis,
* aortic root repair surgery
* aortic dissection
* heart beating surgery,
* heart transplantation

Conditions3

Acute Kidney InjuryCardiac SurgeryHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.